Adaptive Biotechnologies (ADPT) announced that Palmetto GBA, a Medicare Administrative Contractor, MAC, that assesses diagnostic technologies through its Molecular Diagnostics Services Program, MoIDX, has expanded coverage of clonoSEQ to include detection and monitoring of measurable residual disease, MRD, in Medicare patients with mantle cell lymphoma
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT: